Related Experiment Video
Updated: May 25, 2026

Low-Cost, Volume-Controlled Dipstick Urinalysis for Home-Testing
Published on: May 8, 2021
Smartphone-Based Microbubble-Linked Immunosorbent Assay Powered by Classification-Regression Integrated Deep Learning
Xin Tang1, Lian Xue1, Xiang Liu1
1The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics - Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, China.
Abstract:
As the demand for portable, efficient, and precise diagnostic technologies continues to grow in modern healthcare, traditional ELISA systems are increasingly limited by expensive and proprietary equipment. Here, we developed CRiBDL-ELISA (Classification-Regression Integrated Deep Learning Microbubble-Based Enzyme-Linked Immunosorbent Assay), a smartphone-based platform for precise biomarker detection across 5 orders of magnitude. The biomarkers captured on the well plates are labeled with platinum nanoprobes, which generate distinctive bubble patterns in the presence of hydrogen peroxide. A user-friendly smartphone application integrates imaging, YOLO-based object detection, image preprocessing, deep learning inference, and result visualization to enable one-click analysis with real-time feedback. Concentration-dependent bubble patterns captured by the smartphone camera allow precise biomarker quantification without the need for additional optical hardware. The platform achieved a detection limit of 0.001 ng/mL for CRP and PCT, which was enhanced to ∼0.0001 ng/mL for NT-proBNP and cTnI via postprocessing. Quantification demonstrated high accuracy with R2 = 0.9983 and 0.9979 for CRP and PCT, and R2 = 0.9948 and 0.9942 for NT-proBNP and cTnI. Clinical validation showed 100.00% and 97.22% accuracy for CRP and NT-proBNP samples, respectively. Notably, NT-proBNP measurements showed strong concordance with commercial electrochemiluminescence platforms (R2 = 0.97), validating the clinical reliability. This CRiBDL-ELISA platform enables high-throughput biomarker quantification directly from microplates without specialized instrumentation, providing a cost-effective, robust, and portable solution for clinical diagnostics.

